-
Featured Authors
-
Archives
- May 2013
- April 2013
- March 2013
- February 2013
- January 2013
- December 2012
- November 2012
- October 2012
- September 2012
- August 2012
- July 2012
- June 2012
- May 2012
- April 2012
- March 2012
- February 2012
- January 2012
- December 2011
- November 2011
- October 2011
- September 2011
- August 2011
- July 2011
- June 2011
- May 2011
- April 2011
- March 2011
- February 2011
- January 2011
- December 2010
- November 2010
- October 2010
- September 2010
- August 2010
- July 2010
- June 2010
- May 2010
- April 2010
- March 2010
- February 2010
- January 2010
- December 2009
- November 2009
- October 2009
- September 2009
- August 2009
- July 2009
- June 2009
- May 2009
- April 2009
- March 2009
- February 2009
- January 2009
- December 2008
- November 2008
- October 2008
- September 2008
- August 2008
- July 2008
- June 2008
- May 2008
- April 2008
- March 2008
- February 2008
-
Meta
Tag Archives: Investment
IPO Update – Jan 2012
2011 ended quietly for the US biotech IPO market. It has now been almost two months without a biotech IPO. The last few IPOs back in November continued the theme that was in place at the beginning of the year – you can get out, but with a -30% haircut. In fact, only two of the 12 IPOs in 2011 raised more than they filed for. This is shown in chart 1 below. The two Read More >
Opportunity or Apocalypse? Prophecies for 2012
On day two of the BIO Investor Forum in San Francisco, Calif., attendees were eager to participate in the Closing Plenary. Historically, this session draws the biggest crowd of the conference and this year was no exception. Speaking to a packed audience, with standing room only, the panelists engaged in a lively discussion about the state of the industry and what is in the cards for 2012. Both Bryan Roberts, PhD, Partner, Venrock and Matthew Read More >
Policies that Benefit Start-Ups Grow the Bio-Economy
The United States remains the land of entrepreneurialism despite our lingering economic troubles. To maintain our nation’s global leadership and drive job growth, we must continue to create policies that encourage and reward innovation in growth industries — including biotechnology. Jeffrey Bussgang, a general partner at the venture capital firm Flybridge Capital Partners contributed an interesting piece to Fortune/CNN Money in which he points out that start-up companies – not small businesses – are the Read More >
Are Manufacturers and Investors Looking for the Same Thing From Industrial Biotech?
The morning plenary session at BIO’s World Congress featured Jenny Cross from Mohawk Industries, makers of carpets, and Steven Mirshak of DuPont Tate & Lyle, suppliers of a biobased ingredient for Mohawk, discussing what consumers are looking for and how industrial biotech can meet their needs. Cross noted that their consumer research indicates that the typical consumer is looking for quality and durability, with price and “green” attributes coming second. One point that Cross emphasized Read More >
IP Position Critical to Biotech Investment
A great article from Genetic Engineering and Biotechnology News written by Lisa Haile reviewing the Myriad case and its implications for future medical advances. Interesting Quotes: “While it is unfortunate, I have seen quite a few technologies over the years that would be of potential great benefit to patients, but the intellectual property was simply not there to support protecting the product from fast followers in the market place,” explains Robert More, a general partner Read More >
